Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

Creatine may cause hair shedding and texture changes, with mixed user experiences. Combining creatine with finasteride doesn't always prevent these effects, possibly due to individual DHT sensitivity.

A user experienced mild side effects from 0.5mg finasteride daily, including increased estradiol and minor gynecomastia. They are considering taking a low dose of exemestane to reduce estrogen levels.

The user has been using Alpecin and Nizoral, which improved hair texture and reduced shedding and itching. They are hesitant to use finasteride or minoxidil and are seeking other suggestions to slow hair loss and improve hair appearance.

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

A user is seeking help to purchase and ship Alpecin DMG to the United States due to issues with eBay sellers. They prefer Alpecin DMG over minoxidil because of concerns about minoxidil's effects on insulin production, as they have diabetes.

RU58841 in glycerin may cause less irritation than in PG form, but its effectiveness might be reduced. Users discuss the potential trade-off between irritation and efficacy.

People are hopeful for a permanent hair loss solution by the 2030s, considering options like hair cloning and treatments like pp405. Synthetic hair transplants have been attempted but are not effective long-term.

Natural DHT blockers caused negative side effects like weak erections and depression, while finasteride improved overall well-being and cleared acne. Users shared similar experiences, finding finasteride effective without the adverse effects of natural treatments.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The user added P5P (vitamin B6) to their shampoo to reduce scalp itch, which improved significantly. They have been using finasteride for hair loss but are exploring additional treatments like topical antiandrogens and prolactin inhibitors.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

The user reported hair recovery on the scalp after 4 months using finasteride and 5% topical minoxidil, with anxiety as a side effect. Reducing caffeine intake helped manage anxiety, which may be linked to minoxidil's effects.

Soy consumption may help prevent androgenic alopecia, but it can decrease sexual drive in some men. There is a connection between soy and androgenic alopecia, suggesting a potential protective effect.

Caffeine's effectiveness in reversing hair loss is debated, with some users skeptical about caffeine-based products like Alpecin. Alternatives like Nizoral are suggested, but results vary, and some experience side effects from treatments that lower DHT.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

Switching from topical to oral minoxidil resolved issues like watery eyes and ear itchiness. Users report oral minoxidil is better for sensitive skin, though some are concerned about side effects like hair growth everywhere.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

The user is concerned about whether previous use of anti-androgens like fluridil, which caused side effects, will affect future use of finasteride. They have used finasteride briefly in the past and are considering using it again.

The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.

Taking ashwagandha with finasteride is generally not a concern as finasteride blocks DHT conversion, and ashwagandha's effect on testosterone is minimal. Ashwagandha can be beneficial for stress and sleep, but users should monitor for any long-term side effects.

People are discussing hair loss treatments, including finasteride, minoxidil, and dutasteride, focusing on maintenance and potential regrowth. Some users joke about unrealistic expectations, while others share experiences and advice on treatment options.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

The user experienced negative side effects from oral minoxidil, including cardiac issues and excessive sweating, and decided to switch to topical minoxidil while using other treatments like RU58841, Setipiprant, Azelaic acid, and latanoprost. Another user suggested splitting the oral minoxidil dose to reduce side effects.

Zinc supplementation caused significant hair shedding for the user, who had been successfully managing hair loss with finasteride, minoxidil, RU58841, and microneedling. The user discontinued zinc after noticing no libido increase and believes the hair loss was due to zinc's interaction with other minerals or hormonal changes.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

The earliest pp405 might become available is likely between 2027 and 2030, with some users suggesting it could be as late as 2035. Current treatments mentioned include dutasteride and minoxidil.